What Are Senolytics? The Science Behind Targeting Senescent Cells

Senolytic research, explained

Senolytics are compounds being studied for their ability to selectively eliminate certain senescent cells — the damaged or stressed cells sometimes described as “zombie cells.”

Why target senescent cells?

Cellular senescence is a normal biological response. A stressed or damaged cell can permanently stop dividing, which can help prevent potentially dangerous cells from multiplying. Senescence can also play useful roles in processes such as wound healing.

The scientific interest comes from what can happen when some senescent cells persist and accumulate. Certain senescent cells release inflammatory and other signaling molecules collectively known as the senescence-associated secretory phenotype (SASP). Researchers are investigating how this process may contribute to tissue dysfunction and age-related disease.

If you are new to this subject, start with our plain-English guide to zombie cells and cellular senescence.

What does a senolytic do?

Senescent cells can activate survival pathways that help them resist normal programmed cell death. Researchers discovered that interfering with some of these survival mechanisms can make certain senescent cells more vulnerable to elimination.

Compounds designed or investigated for this purpose are called senolytics.

An important complication is that senescent cells are not all identical. Different cell types and tissues can rely on different survival mechanisms. A compound showing senolytic activity in one experimental setting therefore may not behave the same way in another.

Senolytics versus senomorphics

Scientists are studying more than one way of addressing cellular senescence.

Senolytics are intended to selectively eliminate senescent cells. Senomorphics, sometimes called senostatics, generally aim to modify harmful features of senescent cells — including aspects of the SASP — without necessarily killing the cells.

Both approaches fall within the broader field of senotherapeutics.

Where does fisetin fit?

Fisetin is a naturally occurring flavonoid that has attracted attention because laboratory and animal research has identified senolytic or senotherapeutic activity under certain experimental conditions.

That does not establish fisetin as a proven anti-aging treatment in humans. Human research is still developing, and determining effectiveness, safety, appropriate applications and biological effects requires controlled clinical studies.

Read our introduction to fisetin and the research behind it.

What has been tested in humans?

Early human studies have investigated senolytic approaches in specific medical populations. For example, a small pilot study involving nine people with diabetic kidney disease reported reductions in markers associated with senescent cell burden after treatment with the investigational combination of dasatinib and quercetin.

Read what human research actually shows about dasatinib plus quercetin →

Findings like these are scientifically important, but small early-stage studies cannot establish that senolytics broadly slow human aging, extend lifespan, or provide benefits to otherwise healthy people.

Why the science is more complicated than “killing zombie cells”

The zombie-cell metaphor makes cellular senescence easier to understand, but the underlying biology is considerably more complex. Senescence can have beneficial as well as harmful roles, senescent cells differ among tissues, and researchers are still developing reliable ways to identify and measure them in humans.

The central scientific question is therefore not simply whether senescent cells can be removed. Researchers need to determine which cells should be targeted, under what circumstances, with what compounds, and with what effects on human health.

How are senolytics supposed to work?

Senescent cells often activate survival pathways that help them resist programmed cell death. Researchers are investigating whether these survival mechanisms create vulnerabilities that can be targeted selectively.

Senolytic compounds are designed to interfere with some of these pro-survival pathways so that certain senescent cells are more likely to undergo apoptosis, or controlled cell death.

This does not mean that a senolytic simply kills any cell that has stopped dividing. Different senescent cells can rely on different survival mechanisms, which means sensitivity to a particular senolytic may vary by cell type, tissue and cause of senescence.

Why does selectivity matter?

The central challenge of senolytic research is not merely removing cells. It is identifying and targeting senescent cells that are contributing to tissue dysfunction while minimizing effects on healthy cells and potentially beneficial forms of senescence.

Research increasingly shows that senescent cells are heterogeneous. Scientists have identified different patterns of senescence, sometimes called senotypes, across different cell types and tissues.

In 2026, the NIH Cellular Senescence Network reported a major framework for mapping and classifying senescent cells throughout the human body. These findings reinforce the idea that there is unlikely to be one universal senescent-cell target.

See how researchers are mapping different senescent-cell populations →

What kinds of senolytics are researchers studying?

Researchers have investigated several classes of compounds for possible senolytic activity. These include drug combinations, naturally occurring flavonoids and compounds that interfere with specific cellular survival pathways.

Examples studied in the scientific literature include dasatinib plus quercetin, fisetin and experimental inhibitors targeting proteins involved in cell survival.

These compounds should not be treated as interchangeable. Their mechanisms, potency, tissue distribution, safety profiles and effects on different senescent-cell populations can differ substantially.

The term senolytic therefore describes a research strategy rather than one uniform class of treatments with identical effects.

What have animal studies shown?

Much of the enthusiasm surrounding senolytics comes from laboratory and animal studies.

In experimental models, reducing particular senescent-cell populations has been associated with improvements in several measures of tissue function and age-related disease. These studies helped establish cellular senescence as a potential therapeutic target.

However, animal studies cannot establish that the same benefits, risks or treatment effects will occur in humans. Differences in biology, disease processes, drug metabolism and lifespan all complicate translation.

What have early human studies shown?

Early clinical research has provided preliminary evidence that senescent cells can be targeted in humans under some circumstances.

For example, a small open-label study of nine people with diabetic kidney disease reported reductions in several markers associated with senescent cells after treatment with dasatinib plus quercetin. Researchers observed changes in adipose tissue, skin and circulating SASP-related factors.

This was an important proof-of-concept study, but its small size, lack of placebo control and specific patient population mean that the results should not be generalized to healthy adults or to other senolytic compounds.

Other early human studies have investigated senolytic approaches in conditions such as idiopathic pulmonary fibrosis and additional age-related disorders. Larger randomized trials are still needed to determine clinical benefits and risks.

Review what human senolytic trials have found so far →

Why biomarkers matter in senolytic research

One challenge in human senolytic research is determining whether a treatment actually reduces harmful senescent-cell burden.

There is no single universal biomarker that identifies every senescent cell. Researchers often evaluate combinations of markers such as p16, p21, senescence-associated beta-galactosidase, DNA-damage signals and components of the senescence-associated secretory phenotype.

Changes in these markers can provide useful evidence, but they do not automatically prove that a treatment improves long-term health outcomes.

Learn how scientists identify and measure senescent cells →

Can senolytics slow human aging?

At present, there is not enough evidence to conclude that senolytic treatments slow normal human aging or extend human lifespan.

Laboratory and animal studies have generated promising hypotheses, and early human trials are testing whether those findings can translate into meaningful clinical effects.

To establish an anti-aging benefit, researchers would need strong human evidence showing that a senolytic intervention produces durable improvements in clinically meaningful outcomes with an acceptable safety profile.

That level of evidence has not yet been established.

Are all senescent cells harmful?

No. Senescence is part of normal biology and can serve important protective functions.

Senescent cells can help suppress tumor formation by preventing damaged cells from continuing to divide. They can also contribute to wound healing, tissue remodeling and other temporary physiological processes.

This is one reason researchers are cautious about the idea of broadly eliminating senescent cells. The goal is not necessarily to remove every senescent cell, but to understand which persistent populations are harmful and whether they can be targeted safely.

Read why zombie cells are not always bad →

What are the major unanswered questions?

Important scientific questions remain before senolytics could become established treatments for age-related conditions.

• Which senescent-cell populations should be targeted?
• Which biomarkers best show that a senolytic is working?
• How should researchers distinguish beneficial from harmful senescence?
• Which tissues can different senolytic compounds actually reach?
• What are the risks of repeated or long-term treatment?
• Do reductions in senescence markers lead to meaningful improvements in health?

These questions are especially important because senescent cells differ across tissues and diseases. A result observed in one experimental system cannot automatically be generalized to the entire body.

How should senolytic claims be evaluated?

Claims about senolytics should be evaluated according to the level of evidence supporting them.

Laboratory experiments can identify mechanisms. Animal studies can test biological effects in whole organisms. Early human trials can evaluate feasibility, biomarkers and safety. Larger randomized controlled trials are needed to establish whether an intervention produces meaningful clinical benefits.

For this reason, claims that a compound “clears zombie cells,” reverses aging or extends human lifespan should be treated cautiously unless they are supported by strong human evidence.

Read how Zombie Cell Science evaluates emerging research →

The takeaway

Senolytics represent one of the most interesting experimental approaches in modern aging research. Animal and laboratory findings have provided a strong reason to investigate them, and early human studies have begun testing whether the underlying biology can translate to people.

But the field remains under active investigation. Claims about reversing aging or extending human lifespan go beyond what current clinical evidence has established.

Educational information only; not medical advice. Senolytics remain an active area of research, and discussion of a compound does not constitute a recommendation for its use.

• Human Senescence Atlas: Where Zombie Cells Are Found in the Body
• Can You Test for Zombie Cells?